<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005986</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067974</org_study_id>
    <secondary_id>UMN-MT-9507</secondary_id>
    <nct_id>NCT00005986</nct_id>
  </id_info>
  <brief_title>Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>Autologous Transplantation for Chronic Myelogenous Leukemia Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Cyclophosphamide/G-CSF Priming</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.&#xD;
      Colony-stimulating factors such as filgrastim may increase the number of immune cells found&#xD;
      in bone marrow or peripheral blood and may help a person's immune system recover from the&#xD;
      side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy and filgrastim followed by&#xD;
      peripheral stem cell transplantation in treating patients who have chronic myelogenous&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess clinical outcomes, survival, and morbidity of transplantation therapy in patients&#xD;
           with chronic myelogenous leukemia when treated with high dose chemotherapy and&#xD;
           filgrastim (G-CSF) followed by autologous retrovirally transduced peripheral blood stem&#xD;
           cell (PBSC) transplantation.&#xD;
&#xD;
        -  Determine whether this priming treatment can increase the fraction of benign&#xD;
           Philadelphia chromosome (Ph) negative hematopoietic progenitors in PBSC and reduce the&#xD;
           incidence of persistent or recurrent leukemia after autologous transplantation with&#xD;
           mobilized PBSC in these patients.&#xD;
&#xD;
        -  Assess whether retroviral transduction of mobilized PBSC progenitors determines the&#xD;
           contribution of malignant Ph positive progenitors contaminating the graft to relapse&#xD;
           after transplantation in these patients.&#xD;
&#xD;
        -  Determine whether this priming treatment can expand the benign progenitor population in&#xD;
           the PBSC collections from these patients.&#xD;
&#xD;
      OUTLINE: In the priming phase, patients receive cyclophosphamide IV over 2 hours on day 1 and&#xD;
      filgrastim (G-CSF) subcutaneously (SQ) daily beginning on day 4 and continuing until the&#xD;
      completion of leukapheresis. Peripheral blood stem cells (PBSC) are harvested 4-7 times&#xD;
      between days 10 and 21 beginning when blood counts recover (CD34+ cells are selected from 2&#xD;
      of these PBSC collections and transduced with the LN NEO virus prior to cryopreservation).&#xD;
&#xD;
      In the transplant phase, patients who have not received prior radiotherapy receive&#xD;
      cyclophosphamide IV over 2 hours daily on days -7 and -6 and total body irradiation on days&#xD;
      -4 through -1. Autologous PBSC and LN NEO transduced CD34+ cells are reinfused on day 0.&#xD;
      Patients also receive G-CSF IV daily beginning on day 0 and continuing until blood counts&#xD;
      recover.&#xD;
&#xD;
      Patients who have received prior radiotherapy receive oral busulfan every 6 hours on days -10&#xD;
      through -7 and cyclophosphamide IV daily on days -6 through -3. Autologous PBSC and LN NEO&#xD;
      transduced CD34+ cells are reinfused on day 0. Patients also receive G-CSF IV daily beginning&#xD;
      on day 0 and continuing until blood counts recover.&#xD;
&#xD;
      All patients then receive interferon alfa SQ daily until disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed at 3 weeks; at 3, 6, 9, 12, 18, and 24 months; and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 4-26 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal investigator left the university.&#xD;
  </why_stopped>
  <start_date>August 2000</start_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed chronic or accelerated phase chronic myelogenous leukemia&#xD;
&#xD;
               -  Philadelphia chromosome positive OR&#xD;
&#xD;
               -  BCR/ABL rearrangement&#xD;
&#xD;
          -  No blast crisis or post blast crisis&#xD;
&#xD;
          -  No moderate to severe fibrosis defined by bilateral trephine biopsies&#xD;
&#xD;
          -  Not eligible for or refused to participate in allogeneic marrow transplant protocols&#xD;
&#xD;
          -  No splenomegaly (below umbilicus) that does not respond to chemotherapy and/or&#xD;
             radiotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 90-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Normal organ function (except bone marrow)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior interferon alfa allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior hydroxyurea allowed&#xD;
&#xD;
          -  At least 2 months since prior busulfan (at time of PBSC harvest)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine M. Verfaillie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <name_title>Catherine Verfaillie, MD</name_title>
  </responsible_party>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

